The topologically nontrivial Weyl
semimetals have two different types: (i) the standard Weyl cones with
point-like Fermi surfaces (type-I) and (ii) tilted Weyl cones that
appear at the contact of electron and hole pockets (type-II). These
two types of Weyl semimetals have significantly different physical
properties in their thermodynamics and magnetotransport. Here we presented
a compound OsC2 with both types Weyl points (WPs) at the
equilibrium volume. It has 24 type-I WPs in the K
z
= ±0.0241
planes around K (or K′)
points and 12 type-II WPs in the K
z
= ±0.4354
planes
at the projected K (K′) point,
respectively. The type-I WPs are connected by the helix-trimer Fermi
arcs.
Inspired by the experience in CuO-based superconductor that larger spacing distance between CuO planes induced higher superconductivity transition temperature ͑T C ͒, some researchers synthesized ͑Sr 2 ScO 3 ͒ 2 Fe 2 As 2 and ͑Sr 2 VO 3 ͒ 2 Fe 2 As 2 with the spacing distance between FeAs layers as large as 15.66 Å and found a T C of 37.2 K in the latter compound. Our density-functional calculations indicate that the ground states of ͑Sr 2 ScO 3 ͒ 2 Fe 2 As 2 and ͑Sr 2 VO 3 ͒ 2 Fe 2 As 2 are stripe antiferromagnetic and checkerboard antiferromagnetic, respectively. The band structure and Fermi surface of ͑Sr 2 ScO 3 ͒ 2 Fe 2 As 2 are similar to those of LaOFeAs, while those of ͑Sr 2 VO 3 ͒ 2 Fe 2 As 2 show significant difference. In ͑Sr 2 VO 3 ͒ 2 Fe 2 As 2 , both Fe 3d and V 3d states contribute to the Fermi surfaces, which implies that the V 3d states may play important roles in the superconductivity.
The Jahn-Teller (JT) distortion induced orbital order and optical conductivity in SrRuO(3) and CaRuO(3) are investigated by first-principles calculations. The total energy and optical conductivity of all the spin ordering states of SrRuO(3) and CaRuO(3) are calculated in the LDA+U scheme with U(eff) = 2.5 eV. The down-spin t(2g) of Ru show antiferromagnetic-like orbital order in the a-b plane. We observe a d-d transition peak at an energy of about 1.0 eV in the calculated optical conductivity and analyze the reason for it not being observed in previous experiments.
Distinguishing between inflammatory and fibrotic lesions drastically influences treatment decision-making regarding Crohn’s disease. However, it is challenging to distinguish these two phenotypes before surgery. This study investigates the diagnostic yield of shear-wave elastography and computed tomography enterography to distinguish intestinal phenotypes in Crohn’s disease. Thirty-seven patients (mean age, 29.51 ± 11.52; 31 men) were evaluated with average value of shear-wave elastography (Emean) and computed tomography enterography (CTE) scores. The results demonstrated that a positive correlation between the Emean and fibrosis (Spearman’s r = 0.653, p = 0.000). The cut-off value for fibrotic lesions was 21.30 KPa (AUC: 0.877, sensitivity: 88.90%, specificity: 89.50%, 95% CI:0.755~0.999, p = 0.000). The CTE score showed a positive correlation with inflammation (Spearman’s r = 0.479, p = 0.003), and a 4.5-point grading system was the optimal cut-off value for inflammatory lesions (AUC: 0.766, sensitivity: 73.70%, specificity: 77.80%, 95% CI: 0.596~0.936, p = 0.006). Combining these two metrics improved the diagnostic performance and specificity (AUC: 0.918, specificity: 94.70%, 95% CI: 0.806~1.000, p = 0.000). In conclusion, shear-wave elastography can be used to help detect fibrotic lesions and the computed tomography enterography score emerged as a feasible predictor of inflammatory lesions. The combination of these two imaging techniques is proposed to distinguish intestinal predominant phenotypes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.